Applicability limitations and mismatched populations of chimeric antigen receptor T cell immunotherapy

Abstract

In the past ten years, the research have witnessed the emergence of new tumor immune precision targeted therapy CAR-T cells, which has opened up a new path for tumor treatment. CAR-T cell therapy has been approved for the treatment of hematological tumors, but its role in solid tumors is still unsatisfactory, so many studies have explored combination therapies to improve the efficacy of CAR-T therapy in solid tumors, and although CAR-T cell therapy has a good effect on the treatment of hematologic tumors, there are still non-expressed cases.3 Combination immunomodulators. Chimeric antigen receptor T cell therapy is a new type of immunotherapy in the field of tumors, and CAR-T therapy for solid tumors faces many challenges due to the immunosuppressive microenvironment of solid tumors and the heterogeneity of antigen expression. This paper mainly focuses on the range of treated people of chimeric receptor T cells, and roughly summarizes some of the suitable populations through a large number of literature readings and fusion citations, which aims to help more accurately locate the treated population.